Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 177

Sort by

Sort Order Select

Journal Articles

A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma

Peng-Peng Xu, Yue Zhu, Zi-Yang Shi, Li Wang, Shu Cheng, Ying Qian, Yan Zhao, Yang He, Hong-Mei Yi, Bin-shen Ou-yang, Xu-Feng Jiang, Biao Li, Qi Song, Rong-Ji Mu, Wei-Li Zhao

Blood (2025) 146 (21): 2561–2573.

https://doi.org/10.1182/blood.2025028649

Published: 2025

Includes: Supplemental data

Journal Articles

Rapid normalization of platelet counts in patients with refractory thrombocytopenia associated with systemic lupus erythematosus (SLE) following treatment with allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B)

Blood (2025) 146 (Supplement 1): 3031.

https://doi.org/10.1182/blood-2025-3031

Published: 2025

Journal Articles

Impact of TP53 mutation on CD19-chimeric antigen receptor T-cell therapy in large B-cell lymphoma

Ling-Shuang Sheng, Rong Shen, Zi-Xun Yan, Jinghua Zhao, Wen Wu, Wei Li Zhao, Li Wang

Blood (2025) 146 (Supplement 1): 1746.

https://doi.org/10.1182/blood-2025-1746

Published: 2025

Journal Articles

Clinical outcomes and safety of tislelizumab maintenance therapy following autologous stem cell transplantation in patients with relapsed or refractory diffuse large b-cell lymphoma

Meng-Meng Ji, Siyuan Chen, Yige Shen, Li Wang, Shu Cheng, Pengpeng Xu, Wei Tang, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 3732.

https://doi.org/10.1182/blood-2025-3732

Published: 2025

Journal Articles

Transition to IRD maintenance after DRD induction significantly deepens response in transplant-ineligible NDMM: A prospective multicenter study

Qiuqing Xiang, Minqiu Lu, Bin Chu, Lei Shi, Shan Gao, Lijuan Fang, Mengzhen Wang, Shuangnian Xu, Yan Zhu, Li Wang, Junnan Li, Hua Xue, Li Li, Tingting Duan, Ting Zhang, Li Bao

Blood (2025) 146 (Supplement 1): 4059.

https://doi.org/10.1182/blood-2025-4059

Published: 2025

Journal Articles

A phase II study of lenalidomide, zanubrutinib plus obinutuzumab in patients with FLIPI2 high-risk newly diagnosed follicular lymphoma: An interim analysis

Li Wang, Zhong Zheng, Ruichi Li, Pengpeng Xu, Shu Cheng, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 7123.

https://doi.org/10.1182/blood-2025-7123

Published: 2025

Journal Articles

Orelabrutinib plus bendamustine-rituximab (OBR) Versus Bendamustine-rituximab (BR) in transplant-ineligible, intermediate- to high-risk Mantle Cell Lymphoma (MCL)

Li Wang, Jianzhen Shen, Yaohui Huang, Jing Bao, Lin Shen, Pengpeng Xu, Shu Cheng, Hongming Zhu, Weili Zhao

Blood (2025) 146 (Supplement 1): 3599.

https://doi.org/10.1182/blood-2025-3599

Published: 2025

Journal Articles

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

Blood (2025) 146 (Supplement 1): 887.

https://doi.org/10.1182/blood-2025-887

Published: 2025

Journal Articles

Impact of hepatitis b virus infection on long-term prognosis in B-cell lymphoma: A retrospective cohort study

Lin Shen, Wenjing Yang, Li Wang, Mingyue Chen, Wu Lipan Fu Lati, Min Wu, Wensi Qian, Yanhui Xie

Blood (2025) 146 (Supplement 1): 7057.

https://doi.org/10.1182/blood-2025-7057

Published: 2025

Journal Articles

Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera

Blood (2025) 146 (Supplement 1): 2039.

https://doi.org/10.1182/blood-2025-2039

Published: 2025

Journal Articles

Mechanistic study of the Cullin3-CRL3^KEAP1-NRF2 neddylation axis in chemotherapy resistance of Acute Myeloid Leukemia stem cells

Li Wang, Aoshuang Huang, Jishi Wang

Blood (2025) 146 (Supplement 1): 5065.

https://doi.org/10.1182/blood-2025-5065

Published: 2025

Journal Articles

FK506 improves B cell reconstitution after allo-HSCT compared to csa: A real-world study

Hao Zhou, Guangyu Zhou, Wenqiong Xiang, Guilin Ren, Li Wang

Blood (2025) 146 (Supplement 1): 6018.

https://doi.org/10.1182/blood-2025-6018

Published: 2025

Journal Articles

Glofitamab in combination with CD19 CAR-T therapy for high-risk relapsed/refractory large B-cell lymphoma

Rong Shen, Ling-Shuang Sheng, Zi-Xun Yan, Yu-Yue Liang, Wen Wu, Li Wang, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 3744.

https://doi.org/10.1182/blood-2025-3744

Published: 2025

Journal Articles

R-cmop and pola-R-CMP regimens as first-line treatment for diffuse large B-cell lymphoma with cardiac comorbidity: A prospective, single-arm, multicenter study

Jinhua Liang, Yue Li, Haorui Shen, Jiazhu Wu, Hua Yin, Li Wang, Maozhong Xu, Xu Wei

Blood (2025) 146 (Supplement 1): 1920.

https://doi.org/10.1182/blood-2025-1920

Published: 2025

Journal Articles

High HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory peripheral T-cell lymphoma: A single-agent phase IIa study

Ting Niu, Lin LIU, Huijing Wu, Keshu Zhou, Wei Yang, Li Wang, Shu Cheng, Jie Wang, Jinrong Yang, Fei Li, Shiyong Zhou, Yanhong Tong, Ke Tan, Adrian Rui Liang, linyu yang, Lijuan Chen, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 5415.

https://doi.org/10.1182/blood-2025-5415

Published: 2025

Journal Articles

Efficacy and safety of zanubrutinib plus bendamustine-rituximab in newly diagnosed Mantle Cell Lymphoma with TP53 abnormalities or chemotherapy intolerance

Yaohui Huang, Siyi Chen, Shu Cheng, Pengpeng Xu, Wei Li Zhao, Li Wang

Blood (2025) 146 (Supplement 1): 5382.

https://doi.org/10.1182/blood-2025-5382

Published: 2025

Journal Articles

Single-cell transcriptomic profiling reveals tumor-intrinsic heterogeneity and immune-microenvironment dynamics in the order trial for mantle-cell lymphoma

Lu Jiang, Xiaozhong Shen, Weili Zhao, Li Wang

Blood (2025) 146 (Supplement 1): 1792.

https://doi.org/10.1182/blood-2025-1792

Published: 2025

Journal Articles

粪便微生物移植在治疗类固醇难治性胃肠道移植物抗宿主病中的应用

Xiaotian Yang, Ziyi Hao, Yan Wan, Bing Zhang, Li Wang, Sailan Huang, Hong Zhou, Huiran Jiang, Jin Hu, Jiangnan Liu, Yejun Si, Xingxia Zhang, Guoqiang Lin, Yanming Zhang

Blood (2025) 146 (Supplement 1): 7776.

https://doi.org/10.1182/blood-2025-7776

Published: 2025

Journal Articles

The efficacy and safety of venetoclax and azacitidine combined with granulocyte-colony stimulating factor in the treatment of Acute Myeloid Leukemia

Xiaotian Yang, Juan Chen, Ziyi Hao, Yejun Si, Xingxia Zhang, Guoqiang Lin, Bing Zhang, Li Wang, Yan Wan, Sailan Huang, Huiran Jiang, Yanming Zhang

Blood (2025) 146 (Supplement 1): 6970.

https://doi.org/10.1182/blood-2025-6970

Published: 2025

Journal Articles

All 19 subjects with transfusion-dependent β-thalassemia achieved transfusion independence after treatment with RM-001 (autologous HBG1/2 promoter-modified CD34+ hematopoietic stem and progenitor cells)

Rongrong Liu, Li Wang, Hui Xu, Jianpei Fang, Sixi Liu, Xiaolin Yin, Junbin Liang, Xinyu Li, Yue Li, Gaohui Yang, Yaoyun Li, Yali Zhou, Lin Cheng, Yongrong Lai, Junjiu Huang, Xinhua Zhang

Blood (2025) 146 (Supplement 1): 4308.

https://doi.org/10.1182/blood-2025-4308

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma

Rapid normalization of platelet counts in patients with refractory thrombocytopenia associated with systemic lupus erythematosus (SLE) following treatment with allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B)

Impact of TP53 mutation on CD19-chimeric antigen receptor T-cell therapy in large B-cell lymphoma

Clinical outcomes and safety of tislelizumab maintenance therapy following autologous stem cell transplantation in patients with relapsed or refractory diffuse large b-cell lymphoma

Transition to IRD maintenance after DRD induction significantly deepens response in transplant-ineligible NDMM: A prospective multicenter study

A phase II study of lenalidomide, zanubrutinib plus obinutuzumab in patients with FLIPI2 high-risk newly diagnosed follicular lymphoma: An interim analysis

Orelabrutinib plus bendamustine-rituximab (OBR) Versus Bendamustine-rituximab (BR) in transplant-ineligible, intermediate- to high-risk Mantle Cell Lymphoma (MCL)

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

Impact of hepatitis b virus infection on long-term prognosis in B-cell lymphoma: A retrospective cohort study

Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera

Mechanistic study of the Cullin3-CRL3^KEAP1-NRF2 neddylation axis in chemotherapy resistance of Acute Myeloid Leukemia stem cells

FK506 improves B cell reconstitution after allo-HSCT compared to csa: A real-world study

Glofitamab in combination with CD19 CAR-T therapy for high-risk relapsed/refractory large B-cell lymphoma

R-cmop and pola-R-CMP regimens as first-line treatment for diffuse large B-cell lymphoma with cardiac comorbidity: A prospective, single-arm, multicenter study

High HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory peripheral T-cell lymphoma: A single-agent phase IIa study

Efficacy and safety of zanubrutinib plus bendamustine-rituximab in newly diagnosed Mantle Cell Lymphoma with TP53 abnormalities or chemotherapy intolerance

Single-cell transcriptomic profiling reveals tumor-intrinsic heterogeneity and immune-microenvironment dynamics in the order trial for mantle-cell lymphoma

粪便微生物移植在治疗类固醇难治性胃肠道移植物抗宿主病中的应用

The efficacy and safety of venetoclax and azacitidine combined with granulocyte-colony stimulating factor in the treatment of Acute Myeloid Leukemia

All 19 subjects with transfusion-dependent β-thalassemia achieved transfusion independence after treatment with RM-001 (autologous HBG1/2 promoter-modified CD34+ hematopoietic stem and progenitor cells)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only